Nucleic Acid Therapeutics
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 4.5 | Q2 | 69.6% | 1.950 | Q1 | 95.0% |
| 2024 | 4.7 | Q1 | 75.9% | 1.499 | Q1 | 92.2% |
| 2023 | 4.0 | Q2 | 67.5% | 1.252 | Q1 | 90.0% |
| 2022 | 4.0 | Q2 | 63.5% | 1.490 | Q1 | 92.9% |
| 2021 | 4.2 | Q3 | 66.2% | 1.566 | Q1 | 93.6% |
| 2020 | — | — | 2.255 | Q1 | 96.3% | |
| 2019 | — | — | 2.176 | Q1 | 96.2% | |
| 2018 | — | — | 1.488 | Q1 | 91.7% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
2159-3337
ISSN
2159-3345
country
UScoverage
2011-2025